Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)
Sponsor: NRG Oncology
Listed as NCT01081262, this observational or N/A phase trial focuses on Borderline Ovarian Mucinous Tumor and Ovarian Mucinous Cystadenocarcinoma and remains ongoing. Sponsored by NRG Oncology, it has been updated 55 times since 2010, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Study Description(click to expand)PRIMARY OBJECTIVES: I. To determine if capecitabine and oxaliplatin reduces the death rate compared to carboplatin and paclitaxel in women with mucinous adenocarcinoma of the ovary or fallopian tube. II. To determine if bevacizumab reduces the death rate compared to no bevacizumab in women with mucinous adenocarcinoma of the ovary or fallopian tube. SECONDARY OBJECTIVES: I. To determine if capecitabine and oxaliplatin increases the duration of progression-free survival (PFS) compared to carboplatin and paclitaxel in women with mucinous adenocarcinoma of the ovary or fallopian tube. II. To determine if bevacizumab increases the duration of PFS compared to no bevacizumab in women with mucinous adenocarcinoma of the ovary or fallopian tube. III. To compare the response rates for capecitabine and oxaliplatin versus carboplatin and paclitaxel in patients with mucinous adenocarcinoma of the ovary or fallopian tube with measurable disease after initial tumor reductive surgery. IV. To compare the response rates for bevacizumab versus no bevacizumab in patients with mucinous adenocarcinoma of the ovary or fallopian tube with measurable disease after initial tumor reductive surgery. V. To determine the nature and degree of toxicity of capecitabine and oxaliplatin compared with that of carboplatin and paclitaxel in this cohort of patients. VI. To...
PRIMARY OBJECTIVES:
I. To determine if capecitabine and oxaliplatin reduces the death rate compared to carboplatin and paclitaxel in women with mucinous adenocarcinoma of the ovary or fallopian tube.
II. To determine if bevacizumab reduces the death rate compared to no bevacizumab in women with mucinous adenocarcinoma of the ovary or fallopian tube.
SECONDARY OBJECTIVES:
I. To determine if capecitabine and oxaliplatin increases the duration of progression-free survival (PFS) compared to carboplatin and paclitaxel in women with mucinous adenocarcinoma of the ovary or fallopian tube.
II. To determine if bevacizumab increases the duration of PFS compared to no bevacizumab in women with mucinous adenocarcinoma of the ovary or fallopian tube.
III. To compare the response rates for capecitabine and oxaliplatin versus carboplatin and paclitaxel in patients with mucinous adenocarcinoma of the ovary or fallopian tube with measurable disease after initial tumor reductive surgery.
IV. To compare the response rates for bevacizumab versus no bevacizumab in patients with mucinous adenocarcinoma of the ovary or fallopian tube with measurable disease after initial tumor reductive surgery.
V. To determine the nature and degree of toxicity of capecitabine and oxaliplatin compared with that of carboplatin and paclitaxel in this cohort of patients.
VI. To determine the nature and degree of toxicity of bevacizumab in this cohort of patients.
VII. To compare capecitabine and oxaliplatin versus carboplatin and paclitaxel with respect to changes in patient reported neurotoxicity.
VIII. To determine the impact on quality of life (QOL, as measured by the Functional Assessment of Cancer Therapy-Ovarian \[FACT-O\] Trial Outcome Index \[TOI\]) following treatment with the above regimens.
TERTIARY OBJECTIVES:
I. To collect fixed and/or frozen tissue and whole blood for future research studies.
OUTLINE: Patients are randomized to 1 of 4 treatment arms.
ARM I: Patients receive carboplatin intravenously (IV) over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
ARM III: Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
ARM IV: Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III.
After completion of study treatment, patients are followed up at 4-6 weeks, every 3 months for 2 years, and then every 6 months for 3 years.
Status Flow
Change History
55 versions recorded-
May 4, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE3 → None
-
Dec 2025 — May 2026 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
May 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 50 earlier versions
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting PHASE3
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE3
-
Jan 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE3
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE3
-
Dec 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
-
May 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
-
Feb 2023 — May 2023 [monthly]
Active Not Recruiting PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
-
Jun 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
May 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE3
-
Mar 2021 — May 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE3
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE3
-
Apr 2020 — May 2020 [monthly]
Active Not Recruiting PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Active Not Recruiting PHASE3
-
Dec 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE3
-
Sep 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE3
-
Aug 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE3
-
Jul 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE3
-
Apr 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Oct 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This randomized phase III trial studies carboplatin given together with paclitaxel with or without bevacizumab to see how well it works compared with oxaliplatin given together with capecitabine with or without bevacizumab as first-line therapy in treating patients with newly diagnosed stage II-IV, or recurrent (has come back) stage I epithelial ovarian or fallopian tube cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may block tumor growth in different ways by targeting certain cells. It is not yet known which regimen of combination chemotherapy given together with or without bevacizumab is more effective in treating epithelial ovarian cancer or fallopian tube cancer.
Contact Information
- NRG Oncology
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .